India cracks down on unregulated use of GLP-1 weight-loss drugs

India's Health Ministry has warned against the misuse of GLP-1 drugs, which are widely used for weight loss. The alert follows concerns over easy access to generic versions of these medications after patent protections expired. Authorities now stress that such drugs must only be taken under strict medical supervision. The ministry's notice came after cheaper generic alternatives of GLP-1 drugs, including semaglutide, became available in India. Since March 20, 2026, at least six generic versions have been approved and launched by major pharmaceutical firms. Companies like Dr. Reddy's, Zydus, Sun Pharma, and Lupin now offer brands such as Semanext, Livarise, Semaglyntm, Mashematm, and Alterme.

While effective for weight management, these drugs carry serious risks. Side effects include pancreatitis, nausea, vomiting, and potential liver damage. Self-medication without professional guidance can lead to severe health complications.

Dr Naresh Trehan, Chairman and Managing Director of Medanta, reinforced the warning. He advised patients to avoid purchasing GLP-1 drugs over-the-counter or online. According to him, treatment must always be supervised by qualified doctors, endocrinologists, or internists to prevent misuse and harm. The Health Ministry's notice aims to curb unregulated use of GLP-1 drugs following their patent expiry. With generic versions now widely accessible, authorities insist on medical oversight to ensure patient safety. The warning highlights the importance of professional consultation before starting such treatments.